<DOC>
	<DOCNO>NCT01832987</DOCNO>
	<brief_summary>Rationale : Treatment multidrug extensively drug resistant tuberculosis ( MDR/XDR-TB ) real challenge failure response treatment serious side-effects frequently encounter . New , effective drug less side effect therefore urgently need solve problem . Although several new drug TB pipeline , physician currently limit treatment option treatment complicate MDR/XDR-TB case . Therefore , drug develop label infectious disease evaluate TB . Co-trimoxazole consist sulfamethoxazole trimethoprim . Sulfamethoxazole could effective treatment tuberculosis show Forgacs et al . Huang et al . Furthermore , dry blood spot ( DBS ) analysis , exposure co-trimoxazole could analyze blood drop withdraw finger prick paper . This paper suitable storage , transportation subsequently analysis without additional cooling storage requirement . Objective : The main objective prospective clinical trial evaluate pharmacokinetics 960 mg co-trimoxazole TB patient . This clinical trial provide important information PK co-trimoxazole TB patient future study . The second objective calculate T &gt; MIC AUC0-24h/Minimal inhibitory concentration ( MIC ) ratio efficacy predict parameter . Furthermore , analysis dry blood spot clinically validate compare result blood sample withdraw venous blood versus withdrawn finger prick transfer filter paper . Retrospectively , data study use limited sample strategy co-trimoxazole base pharmacokinetic population model construct full PK curve patient . Study design : A prospective pharmacokinetic study . Study population : 12 TB patient . Intervention : 4 6 day , 960 mg co-trimoxazole daily add normal treatment regimen . Main study parameters/endpoints : The pharmacokinetic parameter ( Vd , Cl , AUC , etc ) co-trimoxazole primary endpoint study . The T &gt; MIC AUC0-24h/Minimal inhibitory concentration ( MIC ) ratio likely best predictive parameter efficacy co-trimoxazole treatment calculate range M tuberculosis isolates .</brief_summary>
	<brief_title>Pharmacokinetic Parameters Co-trimoxazole</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>TB Patients normal susceptible Mycobacterium tuberculosis Patients old 17 young 64 year . Pregnancy breast feeding Patients hypersensitivity sulfonamide trimethoprim Concomitant treatment vitamin K antagonist ( acenocoumarol ) Patients preexist renal dysfunction concomitant treatment angiotensin convert enzyme inhibitor potassium spar diuretic ) may exacerbate hyperkalemic effect SXT . Patients treated methotrexate , phenytoin , sulfonylurea ( glibenclamide , gliclazide , glimepiride en tolbutamide ) procainamide hydrochloride . Patients gastrointestinal complaint like diarrhea vomiting ( observe ) Patients experienced adverse effect SXT similar antibiotic drug . Patients HIV AIDS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>co-trimoxazole</keyword>
	<keyword>sulfamethoxazole</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>